A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2018
At a glance
- Drugs SNP 610 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Sinew Pharma
- 26 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Oct 2018.
- 23 Mar 2018 Planned number of patients changed from 44 to 80.
- 11 Mar 2018 Status changed from planning to not yet recruiting.